SRPT
Sarepta Therapeutics, Inc. · Healthcare · Biotechnology
Momentum-inputs (vergelijkbare managers):
breedte van houders -6.7% ·
aandelenstroom -12.4% ·
netto nieuwe posities -7.1%
· formule
Brede distributie: dalende aandelen en minder houders
Alle eigendomscijfers: uitsluitend gevolgde 13F-managers, posities in gewone aandelen, rapportageperiode Q4 2024
| Kwartaal | Houders | Δ | Aandelen | Gerapporteerde waarde | Nieuw | Uitstappen |
|---|---|---|---|---|---|---|
| Q3 2026 | 1 | -1 | 19.39K | $353,037 | n/a | −2 |
| Q2 2026 | 109 | +2 | 83.38M | $1.50B | +13 | −12 |
| Q1 2026 | 111 | +1 | 76.41M | $1.66B | +6 | −6 |
| Q4 2025 | 110 | +2 | 75.97M | $1.63B | +3 | n/a |
| Q3 2025 | 17 | 0 | 44.07M | $848.49M | +2 | −3 |
| Q2 2025 | 15 | -1 | 40.14M | $686.46M | +1 | −2 |
| Q1 2025 | 13 | -1 | 11.03M | $703.96M | +1 | −2 |
| Q4 2024 | 14 | -1 | 10.27M | $1.25B | +2 | −3 |
| Q3 2024 | 14 | +1 | 7.65M | $955.24M | +1 | n/a |
| Q2 2024 | 13 | n/a | 7.85M | $1.24B | n/a | n/a |
| # | Manager | Aandelen | Δ aandelen | Waarde | Hun gewicht | Gehouden | ||
|---|---|---|---|---|---|---|---|---|
| 1 | State Street Global Advisors ✦ (passief) | 4.07M | n/a | $494.85M | 0.0% | n/c | 1 | SEC ↗ |
| 2 | Wellington Management ✦ | 2.07M | -24.1% | $251.54M | 0.0% | ▼ Trim | 3 | SEC ↗ ×8 |
| 3 | Geode Capital Management ✦ (passief) | 1.71M | +0.6% | $207.54M | 0.0% | ▲ Add | 3 | SEC ↗ ×2 |
| 4 | Norges Bank ✦ (passief) | 1.04M | +3.2% | $126.32M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 5 | Citadel Advisors ✦ | 617.82K | -33.3% | $75.12M | 0.1% | ▼ Trim | 3 | SEC ↗ ×2 |
| 6 | T. Rowe Price ✦ | 241.66K | +2.2% | $29.39M | 0.0% | ▲ Add | 3 | SEC ↗ ×2 |
| 7 | Soros Fund Management ✦ | 230.89K | +11.8% | $28.07M | 0.7% | ▲ Add | 2 | SEC ↗ |
| 8 | Adage Capital Partners ✦ | 175.00K | -36.4% | $21.28M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 9 | Two Sigma Investments ✦ | 75.05K | -62.9% | $9.13M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 10 | Fisher Asset Management ✦ | 17.91K | -1.4% | $2.18M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 11 | Millennium Management ✦ | 13.00K | -41.1% | $1.58M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 12 | Bridgewater Associates ✦ | 5.25K | Nieuw | $637,740 | 0.0% | New | 1 | SEC ↗ |
| 13 | D. E. Shaw & Co. ✦ | 3.50K | -83.9% | $425,565 | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 14 | AQR Capital Management ✦ | 1.71K | Nieuw | $208,405 | 0.0% | New | 1 | SEC ↗ ×3 |
"Hun weging" = het aandeel van de positie in de gerapporteerde 13F-aandelenwaarde van die manager: de overtuigingsmaatstaf. ✦ = gecureerde manager.
Nieuwe kopers
| Bridgewater Associates | $637,740 | 0.0% |
| AQR Capital Management | $208,405 | 0.0% |
Verlaten
| Renaissance Technologies | $28.78M | was 0.0% |
| Marshall Wace | $5.36M | was 0.0% |
| Point72 Asset Management | $4.60M | was 0.0% |
Volledige marktcontext: over ALLE 13F-indieners (SEC gestructureerde data, Q1 2026): 339 houders, 102.41M aandelen, $2.16B gerapporteerd. Dit betreft een andere, oudere periode dan de bovenstaande cijfers van het gevolgde universum; beide worden nooit gecombineerd.
Wat de gevolgde houders van dit effect het vaakst nog meer bezitten: aantallen gedeeld eigendom, geen fundamentele relaties.